290 related articles for article (PubMed ID: 20065649)
1. Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies.
Wang X; Das TK; Singh SK; Kumar S
MAbs; 2009; 1(3):254-67. PubMed ID: 20065649
[TBL] [Abstract][Full Text] [Related]
2. Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis.
Wang X; Singh SK; Kumar S
Pharm Res; 2010 Aug; 27(8):1512-29. PubMed ID: 20422267
[TBL] [Abstract][Full Text] [Related]
3. Different binding modes of free and carrier-protein-coupled nicotine in a human monoclonal antibody.
Tars K; Kotelovica S; Lipowsky G; Bauer M; Beerli RR; Bachmann MF; Maurer P
J Mol Biol; 2012 Jan; 415(1):118-27. PubMed ID: 22079050
[TBL] [Abstract][Full Text] [Related]
4. Structural study of the recognition mechanism of tau antibody Tau2r3 with the key sequence (VQIINK) in tau aggregation.
Tsuchida T; Susa K; Kibiki T; Tsuchiya T; Miyamoto K; In Y; Minoura K; Taniguchi T; Ishida T; Tomoo K
Biochem Biophys Res Commun; 2021 Dec; 585():36-41. PubMed ID: 34784549
[TBL] [Abstract][Full Text] [Related]
5. Three-dimensional structures of the free and antigen-bound Fab from monoclonal antilysozyme antibody HyHEL-63(,).
Li Y; Li H; Smith-Gill SJ; Mariuzza RA
Biochemistry; 2000 May; 39(21):6296-309. PubMed ID: 10828942
[TBL] [Abstract][Full Text] [Related]
6. Mutual conformational adaptations in antigen and antibody upon complex formation between an Fab and HIV-1 capsid protein p24.
Monaco-Malbet S; Berthet-Colominas C; Novelli A; Battaï N; Piga N; Cheynet V; Mallet F; Cusack S
Structure; 2000 Oct; 8(10):1069-77. PubMed ID: 11080628
[TBL] [Abstract][Full Text] [Related]
7. Structural Analysis of Der p 1-Antibody Complexes and Comparison with Complexes of Proteins or Peptides with Monoclonal Antibodies.
Osinski T; Pomés A; Majorek KA; Glesner J; Offermann LR; Vailes LD; Chapman MD; Minor W; Chruszcz M
J Immunol; 2015 Jul; 195(1):307-16. PubMed ID: 26026055
[TBL] [Abstract][Full Text] [Related]
8. Potential of mean force for Syrian hamster prion epitope protein--monoclonal fab 3f4 antibody interaction studies.
Wang YT; Su ZY; Liao JM; Chen CL
Eur J Med Chem; 2009 Sep; 44(9):3504-8. PubMed ID: 19304354
[TBL] [Abstract][Full Text] [Related]
9. Controlling the prion propensity of glutamine/asparagine-rich proteins.
Paul KR; Ross ED
Prion; 2015; 9(5):347-54. PubMed ID: 26555096
[TBL] [Abstract][Full Text] [Related]
10. Predictive tools for stabilization of therapeutic proteins.
Voynov V; Chennamsetty N; Kayser V; Helk B; Trout BL
MAbs; 2009; 1(6):580-2. PubMed ID: 20068399
[TBL] [Abstract][Full Text] [Related]
11. Remediating agitation-induced antibody aggregation by eradicating exposed hydrophobic motifs.
Clark RH; Latypov RF; De Imus C; Carter J; Wilson Z; Manchulenko K; Brown ME; Ketchem RR
MAbs; 2014; 6(6):1540-50. PubMed ID: 25484048
[TBL] [Abstract][Full Text] [Related]
12. Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange.
Zhang A; Singh SK; Shirts MR; Kumar S; Fernandez EJ
Pharm Res; 2012 Jan; 29(1):236-50. PubMed ID: 21805212
[TBL] [Abstract][Full Text] [Related]
13. What makes a protein sequence a prion?
Sabate R; Rousseau F; Schymkowitz J; Ventura S
PLoS Comput Biol; 2015 Jan; 11(1):e1004013. PubMed ID: 25569335
[TBL] [Abstract][Full Text] [Related]
14. The effects of glutamine/asparagine content on aggregation and heterologous prion induction by yeast prion-like domains.
Shattuck JE; Waechter AC; Ross ED
Prion; 2017 Jul; 11(4):249-264. PubMed ID: 28665753
[TBL] [Abstract][Full Text] [Related]
15. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.
Muller YA; Chen Y; Christinger HW; Li B; Cunningham BC; Lowman HB; de Vos AM
Structure; 1998 Sep; 6(9):1153-67. PubMed ID: 9753694
[TBL] [Abstract][Full Text] [Related]
16. Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions.
Agrawal NJ; Kumar S; Wang X; Helk B; Singh SK; Trout BL
J Pharm Sci; 2011 Dec; 100(12):5081-95. PubMed ID: 21789769
[TBL] [Abstract][Full Text] [Related]
17. Crystallographic analysis of the interaction between cyclosporin A and the Fab fragment of a monoclonal antibody.
Vix O; Rees B; Thierry JC; Altschuh D
Proteins; 1993 Apr; 15(4):339-48. PubMed ID: 8460105
[TBL] [Abstract][Full Text] [Related]
18. Sequence features governing aggregation or degradation of prion-like proteins.
Cascarina SM; Paul KR; Machihara S; Ross ED
PLoS Genet; 2018 Jul; 14(7):e1007517. PubMed ID: 30005071
[TBL] [Abstract][Full Text] [Related]
19. Aggregation-prone motifs in human immunoglobulin G.
Chennamsetty N; Helk B; Voynov V; Kayser V; Trout BL
J Mol Biol; 2009 Aug; 391(2):404-13. PubMed ID: 19527731
[TBL] [Abstract][Full Text] [Related]
20. Structural studies on the folded domain of the human prion protein bound to the Fab fragment of the antibody POM1.
Baral PK; Wieland B; Swayampakula M; Polymenidou M; Rahman MH; Kav NN; Aguzzi A; James MN
Acta Crystallogr D Biol Crystallogr; 2012 Nov; 68(Pt 11):1501-12. PubMed ID: 23090399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
